Basilard BioTech - California, Trinidad and Tobago

Basilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called Celletto™. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of current viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more cost-effective production of cell and gene therapies.
Cell and Gene Therapies have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and kill millions of people. The main challenges now  

Show more

are improving upon the limitations of biological and ex-vivo gene delivery and scaling manufacturing (cost-effectively) to meet the needs of current/future cell therapies.
Gene delivery is becoming an increasingly critical bottleneck in the engineering of many Cell and Gene Therapies (CGT) because it is well established that the high cost, lag time, and supply chain limitations associated with viral vectors will prevent them from being a viable long term solution. Awareness of this bottleneck is driving the focus on and need for new, better non-viral delivery technologies.
Basilard is now poised to step into this opportunity and we are looking forward helping enable go-to-market plans for the current, and accelerate the discovery, development, and manufacture of the next generation of revolutionary CGTs.
This is the bottleneck Celletto™ addresses with our new, disruptive, IP Protected mechanoporation solution that offers a better, mechanical (rather than biological), approach to gene delivery. Celletto™ delivers virtually any gene to the nucleus of cells, en masse, without compromising their viability. In doing so, Celletto™ presents a disruptive new paradigm that will transform the engineering of cell-based therapies by reducing cost and increasing versatility relative to prevailing biological delivery methods (i.e., viral vectors), and increasing efficiency and safety compared to existing and emerging chemical and physical methods (e.g., electroporation, shear poration, chemical poration, etc.).